Research on Adverse Drug Reaction Monitoring Based on Chinese Hospital Pharmacovigilance System

doi:10.19803/j.1672-8629.2020.10.05

Abstract

Abstract: Objective To analyze the effect of adverse drug reactions (ADRs) monitoring by Chinese Hospital Pharmacovigilance System (CHPS), so as to provide reference for ADRs monitoring in Chinese medical institutions. Methods The ADR reports reported one year before and after the application of CHPS in our hospital were selected, and the report situation and the quality of report form in the two periods were statistically analyzed, to evaluate the application effect of CHPS. Results After the application of CHPS, the total number of reports increased from 60 to 174, and the total number of active monitoring reports by pharmacists increased from 25 to 99. The average time for each report was shortened from 35.39mins to 15.77mins, and the rate of unqualified reports decreased from 40.63% to 3.23%. Conclusion The establishment and application of CHPS has effectively improved the level of ADR monitoring and management in hospitals, which is of great significance for further strengthening the pharmacovigilance in Chinese hospitals.

Key words: Chinese hospital pharmacovigilance system, adverse drug reaction

CLC Number:

R994.11

MO Kai, NONG Li, CAO Wen, ZHONG Hui, WANG Yanning, LAN Xiaobu. Research on Adverse Drug Reaction Monitoring Based on Chinese Hospital Pharmacovigilance System[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 672-675.

References

[1] Wen RL, Li LH, Luo WT, et al.Study on the application effects of ADR rapid reporting system in the hospital[J]. China Pharmacy(中国药房), 2017, 28(20): 2784-2786.
[2] Li JM.Strengthen management and improve the quantity and quality analysis of adverse drug reaction reports[J]. Capital Medicine(首都医药), 2013 (12): 37-39.
[3] Hu WJ, Cai JF.The current situation and existing problems of monitoring adverse reactions caused by drugs in China[J]. Contemporary Medical Symposium(当代医药论丛), 2018, 16(14): 128-129.
[4] Ren LQ.Analysis of adverse drug reaction reports from 2011 to 2013[J]. Chinese Remedies & Clinics(中国药物与临床), 2015, 15(8): 1184-1186.
[5] Shu T, Chen WG, Hou YF, et al.Research and application of the sentinel hospital pharmacovigilance system based on HIS[J]. China Pharmacy(中国药房), 2017, 28(25): 3468-3471.
[6] State Food and Drug Administration. Annual report of national ADR monitoring (2017) [EB/OL]. (2018-04-10)[2019-10-11]. http://www.nmpa.gov.cn/WS04/CL2138/227761.html.
[7] Zhou H, Jin H H, Qin JF, et al.Establishment and Application of Intelligent Reporting System for Adverse Drug Reactions in Hospitals[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2): 93-97,110.
[8] Wang CH X.Influence of clinical pharmacist intervention on adverse drug reaction monitoring[J]. Medical Journal of Chinese People's Health(中国民康医学), 2019, 31(24): 37-39.
[9] Li X, Yu Q, Guo YM.Application analysis of rapid reporting system of adverse drug reactions in our hospital[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2018, 15(3): 173-176.
[10] Zheng Q, Zheng ZQ, Yang SH, et al.Problems and Countermeasures of ADR monitoring under the new situation of medical reform[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2018, 11(7): 162-164.
[11] Bao HL, Li JF, Wu ZA.Analysis on Influencing Factors of Quality of Adverse Drug Reaction Reports in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(4): 226-229.
[12] Wei He, Difei Yao, Yangmin, Hu, et al.Analysis of a Pharmacist-Led Adverse Drug Event Management Model for Pharmacovigilance in an Academic Medical Center Hospital in China[J]. Ther Clin Risk Manag, 2018(14): 2139-2147.
[13] Zhang XM, Xu MD, Chen WG, et al.Research on National Sentinel Alliance for Adverse Drug Reaction Surveillance Based on CHPS[J]. Chinese Pharmaceutical Affairs(中国药事), 2019, 33(2): 137-142.
[14] Zhou Y, Zhang YJ.Analysis and monitoring of adverse drug reactions[J]. Strait Pharmaceutical Journal(海峡药学), 2019, 31(9): 268-270.
[15] Xinling Li, Haona Li, Jianxiong Deng, et al.Active Pharmacovi- gilance in China: Recent Development and Future Perspectives[J]. Eur J Clin Pharmacol, 2018, 74(7): 863-871.